Taxoids and Multidrug Resistance

作者: Robert A. Newman , Dominic Fan

DOI: 10.1007/978-1-4615-9852-7_8

关键词:

摘要: Taxol is now recognized as one of the most interesting and promising new drugs derived from natural products to enter clinical trials for treatment cancer in many years. Its importance international movement preserve biodiversity has been profound far-reaching, it represents proof potential value products, particularly those rapidly disappearing forests this planet (Junod 1991). Originally regarded tree death, toxic constituents portions yew were known long ago time Julius Caesar (Kingston 1994). Tales poison associated with bark western (Taxus brevifolia), an evergreen found Pacific Northwest, told years by native Americans but antitumor activity taxol present within itself was discovered only recently (Suffness 1989). The small, slow-growing little commercial generally cut burned larger more valuable fir, spruce pine trees are harvested.

参考文章(79)
T Brown, K Havlin, G Weiss, J Cagnola, J Koeller, J Kuhn, J Rizzo, J Craig, J Phillips, D Von Hoff, A phase I trial of taxol given by a 6-hour intravenous infusion. Journal of Clinical Oncology. ,vol. 9, pp. 1261- 1267 ,(1991) , 10.1200/JCO.1991.9.7.1261
B S Reichman, A D Seidman, J P Crown, R Heelan, T B Hakes, D E Lebwohl, T A Gilewski, A Surbone, V Currie, C A Hudis, Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. Journal of Clinical Oncology. ,vol. 11, pp. 1943- 1951 ,(1993) , 10.1200/JCO.1993.11.10.1943
H Burris, R Irvin, J Kuhn, S Kalter, L Smith, D Shaffer, S Fields, G Weiss, J Eckardt, G Rodriguez, Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. Journal of Clinical Oncology. ,vol. 11, pp. 950- 958 ,(1993) , 10.1200/JCO.1993.11.5.950
A I Einzig, P H Wiernik, J Sasloff, C D Runowicz, G L Goldberg, Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. Journal of Clinical Oncology. ,vol. 10, pp. 1748- 1753 ,(1992) , 10.1200/JCO.1992.10.11.1748
J H Schiller, B Storer, K Tutsch, R Arzoomanian, D Alberti, C Feierabend, D Spriggs, Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. Journal of Clinical Oncology. ,vol. 12, pp. 241- 248 ,(1994) , 10.1200/JCO.1994.12.2.241
W.C. Mertens, E.A. Eisenhauer, J. Jolivet, S. Ernst, M. Moore, A. Muldal, Docetaxel in advanced renal carcinoma A phase II trial of the National Cancer Institute of Canada Clinical Trials Group Annals of Oncology. ,vol. 5, pp. 185- 187 ,(1994) , 10.1093/OXFORDJOURNALS.ANNONC.A058776
Embrey Wm, Johnson Rk, Gregory Eb, Chitnis Mp, In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer treatment reports. ,vol. 62, pp. 1535- ,(1978)
Fujimoto S, [Schedule dependency of i.v.-paclitaxel against SC-M 109 mouse lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. ,vol. 21, pp. 671- ,(1994)
Ringel I, Horwitz Sb, Rao S, Shen Hj, Cohen D, Yang Cp, Taxol: mechanisms of action and resistance. Journal of The National Cancer Institute Monographs. pp. 55- 61 ,(1993)